Collectively, these results indicated that the dual modulation involving TLR4/NF-κB pathway suppression and Nrf2/HO-1 pathway activation underpins the therapeutic superiority of HES-CUR NPs in mitigating ulcerative colitis relative to the other treatments. This evidence concerns the gene TLR4 and ulcerative colitis.